Clinical Trials
407
Active:19
Completed:51
Trial Phases
6 Phases
Early Phase 1:4
Phase 1:16
Phase 2:86
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (230 trials with phase data)• Click on a phase to view related trials
Not Applicable
87 (37.8%)Phase 2
86 (37.4%)Phase 3
22 (9.6%)Phase 1
16 (7.0%)Phase 4
15 (6.5%)Early Phase 1
4 (1.7%)QL1706 Plus Neoadjuvant Chemotherapy Followed by Type I Hysterectomy for Locally Advanced Cervical Cancer
Not Applicable
Active, not recruiting
- Conditions
- Neoadjuvant ImmunotherapyLocally Advanced Cervical Cancer
- Interventions
- Drug: QL1706+TC
- First Posted Date
- 2025-10-03
- Last Posted Date
- 2025-10-03
- Target Recruit Count
- 54
- Registration Number
- NCT07205497
- Locations
- 🇨🇳
The Sun Yat-sen Memorial Hospital of the Sun Yat-sen University, Guangzhou, Guangdong, China
Regional Radiotherapy Omission in Low-Risk Node Positive Breast Cancer
Recruiting
- Conditions
- Breast Cancer
- First Posted Date
- 2025-09-18
- Last Posted Date
- 2025-09-18
- Target Recruit Count
- 635
- Registration Number
- NCT07179744
- Locations
- 🇨🇳
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
Methylprednisolone Sodium Succinate With Endovascular ThRombectomy for Large Ischemic STroke
Not Applicable
Not yet recruiting
- Conditions
- Ischemic Stroke, Acute
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-09-16
- Last Posted Date
- 2025-09-16
- Target Recruit Count
- 912
- Registration Number
- NCT07175649
- Locations
- 🇨🇳
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
Efficacy and Safety of Sacituzumab in Patients With OCCC After Immunotherapy Progression
Not yet recruiting
- Conditions
- Ovarian CancerAntibody-drug ConjugatesClear Cell Adenocarcinoma of Ovary
- First Posted Date
- 2025-09-11
- Last Posted Date
- 2025-09-11
- Target Recruit Count
- 22
- Registration Number
- NCT07168083
A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer
Not Applicable
Not yet recruiting
- Conditions
- Cervical Cancer MetastaticCervical Cancer Recurrent
- Interventions
- Drug: Famitinib + Camrelizumab
- First Posted Date
- 2025-08-27
- Last Posted Date
- 2025-08-27
- Target Recruit Count
- 120
- Registration Number
- NCT07143292
- Prev
- 1
- 2
- 3
- 4
- 5
- 81
- Next
News
No news found